Assessment of prolonged proteasome inhibition through ixazomib‐based oral regimen on newly diagnosed and first‐relapsed multiple myeloma: A real‐world Chinese cohort study

This is the authors' abstract. We don't add key points for this paper.

To evaluate the effectiveness, safety, and convenience of in-class transition (iCT) from intravenous bortezomib-based induction to ixazomib-based oral regimens.